Major share buyback by Trinity Biotech after FDA sinks cardiac test
Company says it has around $85 million of cash in the bank
Trinity Biotech, the Bray-based maker of medical diagnostic equipment, plans to “aggressively” buy back its stock in a bid to lift its share price, which collapsed this month after it failed to secure regulatory approval for a new test for heart attacks.
The company said last week that it had about $85 million of cash in the bank and while it had looked at a number of potential acquisitions to boost its growth, ...
